Hepregen Announces Appointment of Dr. Michael Holsapple
News Aug 07, 2013
Hepregen Corporation has announced the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development.
This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute (“Battelle”), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle.
Following a successful 13-year academic career, Dr. Holsapple was leader of the Immunotoxicology and Respiratory Toxicology groups at Dow Chemical for eight years, after which, from 2002 to 2011, he served as the Executive Director of the Health and Environmental Sciences Institute (HESI), the global branch of the International Life Sciences Institute (ILSI) in Washington, DC.
He joined Battelle in 2011 as a Senior Leader Research in systems toxicology. Dr. Holsapple received the Society of Toxicology (SOT) Achievement Award in 1992.
In recognition of his contributions to immunotoxicology, he received the Vos Award: Career Achievement in Immunotoxicology in 2009.
Dr. Holsapple has served on Council for the SOT, and on Council for the American College of Toxicology (ACT). He was elected a ‘fellow’ in the Academy of Toxicological Sciences (ATS) in 2006, and a member of the Board of Trustees of the ATS in 2013. He is also a past President of the SOT.
Dr. Holsapple stated, “Hepregen has become the leader in next generation in vitro micro-liver products. Joining the Company’s outstanding team of scientists and commercially experienced senior managers is without a doubt an exceptional opportunity to participate in development of products that can transform the pharmaceutical, cosmetics and chemical industries.”
“Mike’s incredibly extensive scientific and organizational background in the field of toxicology provides Hepregen with an unmatched resource,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer, adding, “He brings a wealth of knowledge and experience to our emerging global enterprise.”
In a new study published in Cell Stem Cell, a team of researchers have demonstrated, using fat cells derived from human stem cells, that individual genetic variation can be used to predict whether the TZD rosiglitazone will produce the unwanted side effect of increasing cholesterol levels in certain individuals.READ MORE